557 related articles for article (PubMed ID: 26811177)
1. Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs.
Phillips RM
Cancer Chemother Pharmacol; 2016 Mar; 77(3):441-57. PubMed ID: 26811177
[TBL] [Abstract][Full Text] [Related]
2. Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia.
Guise CP; Mowday AM; Ashoorzadeh A; Yuan R; Lin WH; Wu DH; Smaill JB; Patterson AV; Ding K
Chin J Cancer; 2014 Feb; 33(2):80-6. PubMed ID: 23845143
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia-activated prodrugs: paths forward in the era of personalised medicine.
Hunter FW; Wouters BG; Wilson WR
Br J Cancer; 2016 May; 114(10):1071-7. PubMed ID: 27070712
[TBL] [Abstract][Full Text] [Related]
4. Targeting Hypoxia: Hypoxia-Activated Prodrugs in Cancer Therapy.
Li Y; Zhao L; Li XF
Front Oncol; 2021; 11():700407. PubMed ID: 34395270
[TBL] [Abstract][Full Text] [Related]
5. The role of hypoxia-activated prodrugs in cancer therapy.
Denny WA
Lancet Oncol; 2000 Sep; 1(1):25-9. PubMed ID: 11905684
[TBL] [Abstract][Full Text] [Related]
6. Targeting DNA topoisomerase IIα (TOP2A) in the hypoxic tumour microenvironment using unidirectional hypoxia-activated prodrugs (uHAPs).
Smith PJ; McKeown SR; Patterson LH
IUBMB Life; 2023 Jan; 75(1):40-54. PubMed ID: 35499745
[TBL] [Abstract][Full Text] [Related]
7. A Novel Model System for Understanding Anticancer Activity of Hypoxia-Activated Prodrugs.
Sun Z; Zhang H; Wu J; Gao F; Zhang C; Hu X; Liu Q; Wei Y; Zhuang J; Huang X
Mol Pharm; 2020 Jun; 17(6):2072-2082. PubMed ID: 32352301
[TBL] [Abstract][Full Text] [Related]
8. Clinical Advances of Hypoxia-Activated Prodrugs in Combination With Radiation Therapy.
Mistry IN; Thomas M; Calder EDD; Conway SJ; Hammond EM
Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1183-1196. PubMed ID: 28721903
[TBL] [Abstract][Full Text] [Related]
9. Homologous recombination repair-dependent cytotoxicity of the benzotriazine di-N-oxide CEN-209: comparison with other hypoxia-activated prodrugs.
Hunter FW; Wang J; Patel R; Hsu HL; Hickey AJ; Hay MP; Wilson WR
Biochem Pharmacol; 2012 Mar; 83(5):574-85. PubMed ID: 22182429
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia-activated prodrugs in cancer therapy: progress to the clinic.
Denny WA
Future Oncol; 2010 Mar; 6(3):419-28. PubMed ID: 20222798
[TBL] [Abstract][Full Text] [Related]
11. Investigational Hypoxia-Activated Prodrugs: Making Sense of Future Development.
Su MX; Zhang LL; Huang ZJ; Shi JJ; Lu JJ
Curr Drug Targets; 2019; 20(6):668-678. PubMed ID: 30468124
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia Activated Prodrugs: Factors Influencing Design and Development.
Liang D; Miller GH; Tranmer GK
Curr Med Chem; 2015; 22(37):4313-25. PubMed ID: 26487420
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia-targeted drug delivery.
Sharma A; Arambula JF; Koo S; Kumar R; Singh H; Sessler JL; Kim JS
Chem Soc Rev; 2019 Feb; 48(3):771-813. PubMed ID: 30575832
[TBL] [Abstract][Full Text] [Related]
14. Perfluorocarbon regulates the intratumoural environment to enhance hypoxia-based agent efficacy.
Wang W; Cheng Y; Yu P; Wang H; Zhang Y; Xu H; Ye Q; Yuan A; Hu Y; Wu J
Nat Commun; 2019 Apr; 10(1):1580. PubMed ID: 30952842
[TBL] [Abstract][Full Text] [Related]
15. Combining hypoxia-activated prodrugs and radiotherapy in silico: Impact of treatment scheduling and the intra-tumoural oxygen landscape.
Hamis S; Kohandel M; Dubois LJ; Yaromina A; Lambin P; Powathil GG
PLoS Comput Biol; 2020 Aug; 16(8):e1008041. PubMed ID: 32745136
[TBL] [Abstract][Full Text] [Related]
16. The flavoprotein FOXRED2 reductively activates nitro-chloromethylbenzindolines and other hypoxia-targeting prodrugs.
Hunter FW; Jaiswal JK; Hurley DG; Liyanage HD; McManaway SP; Gu Y; Richter S; Wang J; Tercel M; Print CG; Wilson WR; Pruijn FB
Biochem Pharmacol; 2014 May; 89(2):224-35. PubMed ID: 24632291
[TBL] [Abstract][Full Text] [Related]
17. Prospects for bioreductive drug development.
Phillips RM
Expert Opin Investig Drugs; 1998 Jun; 7(6):905-28. PubMed ID: 15992006
[TBL] [Abstract][Full Text] [Related]
18. AQ4N: a new approach to hypoxia-activated cancer chemotherapy.
Patterson LH; McKeown SR
Br J Cancer; 2000 Dec; 83(12):1589-93. PubMed ID: 11104551
[TBL] [Abstract][Full Text] [Related]
19. Precise gliomas therapy: Hypoxia-activated prodrugs sensitized by nano-photosensitizers.
Zhang H; Shi C; Han F; Li M; Ma H; Sui R; Long S; Sun W; Du J; Fan J; Piao H; Peng X
Biomaterials; 2022 Oct; 289():121770. PubMed ID: 36075142
[TBL] [Abstract][Full Text] [Related]
20. Assessing the therapeutic response of tumors to hypoxia-targeted prodrugs with an in silico approach.
Yilmaz D; Tuzer M; Unlu MB
Math Biosci Eng; 2022 Aug; 19(11):10941-10962. PubMed ID: 36124576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
